PCSK9 inhibitors: effectiveness of treatment and changes in background lipid-lowering therapy in a real world Italian population. The AT-TARGET-IT study

26 August 2022 (14:15 - 15:00)

Organised by:

Abstract

Sign in to view the resources

Slides

About the speaker

Doctor Christian Basile

Karolinska Institute, Stockholm (Sweden)

5 More presentations in this session

Presentation thumbnail

Correlation of lipoprotein (a) with parameters of lipid profile and other cardiovascular risk factors in patients with familial combined hyperlipidemia

Doctor I. Andrikou (Athens, GR)

Abstract Slides

Presentation thumbnail

Cost-effectiveness of cholesterol-lowering drugs for secondary cardiovascular prevention in the UK: ezetimibe, evolocumab, and alirocumab

Doctor T. Michaeli (Mannheim, DE) Doctor D. Michaeli (Mannheim, DE)

Abstract Slides

Presentation thumbnail

Recurrent atherosclerotic cardiovascular disease events preventable with guideline recommended lipid-lowering treatment following myocardial infarction

Doctor R. Rosenson (New York City, US)

Abstract Slides

Presentation thumbnail

Simulation of bempedoic acid in the lipid-lowering treatment pathway using the European contemporary SANTORINI cohort of high- and very high-risk patients

Doctor A. Bilitou (Munich, DE)

Abstract Slides

Presentation thumbnail

Worldwide comparative efficacy of nutraceuticals on lipid profile. an updated systematic review and network meta-analysis

Doctor T. Osadnik (Zabrze, PL)

Abstract Slides

Access the full session

Session thumbnail

Lipids - Drug therapy 1

The Event

Event poster

ESC Congress 2022

26 August 2022 14:15 CET

You may be interested in

Webinar

Unmet needs in lipid management: treatment goals and how to achieve them

Webinar

Risk assessment and lipid management in primary prevention

Congress Presentation

Optimal medical therapy for primary prevention

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources